Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy
Animal Models and Experimental Medicine · 2023
DOI: 10.1002/ame2.12352 ↗Kurz gefasst
Fachartikel in der Zeitschrift Animal Models and Experimental Medicine, 2023. Verfasst von Miaomiao Gong und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, China. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Patients with pancreatic ductal adenocarcinoma (PDAC) who undergo surgical resection and receive effective chemotherapy have the best chance for long‐term survival. Unfortunately, because of the heterogeneity of pancreatic cancer, it is difficult to find a personalized treatment strategy for patients. Organoids are ideal preclinical models for personalized medicine. Therefore, we explore the cultivation conditions and construction methods of PDAC organoid models to screen the individualized therapy strategy.
Methods
Fresh PDAC tissues from surgical resection were collected and digested with digestive enzymes; then the tumor cells were embedded in Matrigel with a suitable medium to establish the PDAC organoid models. The genetic stability of the organoids was analyzed using whole exon sequencing; hematoxylin and eosin staining and immunohistochemistry of organoids were performed to analyze their consistency with the pathological morphology of the patient's tumor tissue; After 2 days of organoid culture, we selected four commonly used clinical chemotherapy drugs for single or combined treatment to analyze drug sensitivity.
Results
Two cases of PDAC organoid models were successfully established, and the results of their pathological characteristics and exome sequencing were consistent with those of the patient's tumor tissue. Both PDAC organoids showed more sensitivity to gemcitabine and cisplatin, and the combined treatment was more effective than monotherapy.
Conclusion
Both organoids better retained the pathological characteristics, genomic stability, and heterogeneity with the original tumor. Individual PDAC organoids exhibited different sensitivities to the same drugs. Thus, this study provided ideal experimental models for screening individualized therapy strategy for patients with PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Cancer Biology, Laboratory Animal Center, Fourth Military Medical University, Xi'an, China.
- School of Basic Medical Sciences, Medical College of Yan'an University, Yanan, China.
- Animal Experiment Center, Guangzhou University of Chinese Medicine, Guangzhou, China.
- Department of Hepatobiliary and Pancreaticosplenic Surgery, Xijing Hospital, Fourth Military Medical University, Xi'an, China.
ORCID-Profile: Changhong Shi
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Gong, M., Meng, H., Tan, D., Li, P., Qin, J., An, Q., Shi, C., & An, J. (2023). Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy. Animal Models and Experimental Medicine. https://doi.org/10.1002/ame2.12352
Vancouver
Gong M, Meng H, Tan D, Li P, Qin J, An Q, et al. Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy. Animal Models and Experimental Medicine. 2023. doi:10.1002/ame2.12352
BibTeX
@article{Gong2023,
author = {Gong, Miaomiao and Meng, Han and Tan, Dengxu and Li, Peng and Qin, Jing and An, Qingling and Shi, Changhong and An, Jiaze},
title = {Establishment of organoid models for pancreatic ductal adenocarcinoma and screening of individualized therapy strategy},
journal = {Animal Models and Experimental Medicine},
year = {2023},
doi = {10.1002/ame2.12352}
}
EUVIMED